• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Galapagos Receives Transparency Notifications from Bank of America

    2/10/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email

    Mechelen, Belgium; February 10, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America.

    Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 5, 6, and 9, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos' voting rights on February 2, 2026, followed by its controlled entity, BofA Securities, Inc., individually crossing the threshold of 5% on February 3, 2026, as a result of an acquisition of Galapagos' voting rights and equivalent financial instruments. Subsequently, Galapagos received a notification indicating that BofA Securities, Inc. fell below the 5% threshold of Galapagos' voting rights again on February 4, 2026 following the disposal of such instruments, and another notification indicating that the controlling entity, Bank of America Corporation, crossed below the 5% threshold linked to equivalent financial instruments on February 5, 2026 following the disposal of such equivalent financial instruments.

    On February 5, 2026, the Bank of America Corporation (taking into account the holding of its affiliates) owned 132,087 voting rights and 3,323,941 equivalent financial instruments, representing together 5.04% of Galapagos' currently outstanding 65,897,071 shares, versus 250,370 voting rights and 3,264,761 equivalent financial instruments, representing together 5.33%, in the initial notification of February 5 2026.

    Summary of the transactions:

    Date on which the threshold was crossedDate of notificationDirect voting rights after the transactionEquivalent financial instruments after the transactionTotal (%)

    voting rights
    February 2, 2026February 5, 20260.38%4.95%5.33%
    February 3, 2026February 6, 20260.41%6.82%7.23%
    February 4, 2026February 6, 20260.40%5.28%5.68%
    February 5, 2026February 9, 20260.20%4.84%5.04%

    Content of the notifications from Bank of America Corporation:

    The notification dated February 9, 2026, contains the following information:

    • Date of notification: February 9, 2026
    • Date on which the threshold is crossed: February 5, 2026
    • Threshold of voting rights crossed (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation00 0.00% 
    Bank of America, National Association12,47512,475 0.02% 
    Merrill Lynch International237,869105,026 0.16% 
    Managed Account Advisors LLC33 0.00% 
    BofA Securities, Inc.00 0.00% 
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
    14,46214,462 0.02% 
    U.S. Trust Company of Delaware121121 0.00% 
    Subtotal269,930132,087 0.20% 
     TOTAL132,08700.20%0.00%



    B) Equivalent financial instrumentsAfter the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  151,4000.23%physical
    BofA Securities, Inc.Right to Recall  29,4000.04%physical
    BofA Securities, Inc.Rights of Use  2,844,6184.32%physical
    Merrill Lynch InternationalRights of Use  4,2640.01%physical
    Bank of America, National AssociationPhysical Call Option19/06/2026 100,0000.15%physical
    Bank of America, National AssociationSwaps15/06/2026 12,5000.02%cash
    Bank of America, National AssociationSwaps15/01/2027 4,2160.01%cash
    Bank of America, National AssociationSwaps15/10/2027 150.00%cash
    Bank of America, National AssociationSwaps31/01/2028 2890.00%cash
    Merrill Lynch InternationalSwaps15/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps15/01/2027 15,4050.02%cash
    Merrill Lynch InternationalSwaps15/10/2027 150.00%cash
    Merrill Lynch InternationalSwaps30/04/2026 10,6100.02%cash
    Merrill Lynch InternationalSwaps02/07/2026 1,2370.00%cash
    Merrill Lynch InternationalSwaps01/11/2027 4,9490.01%cash
    Merrill Lynch InternationalSwaps29/01/2027 1240.00%cash
    Merrill Lynch InternationalSwaps27/02/2026 3120.00%cash
     TOTAL  3,191,8544.84% 



    TOTAL (A&B)# of voting rights% of voting rights
     3,323,9415.04%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    The notification dated February 6, 2026, contains the following information:

    • Date of notification: February 6, 2026
    • Date on which the threshold is crossed: February 4, 2026
    • Threshold of voting rights crossed (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation00 0.00% 
    Bank of America, National Association12,49312,475 0.02% 
    Merrill Lynch International242,319237,869 0.36% 
    Managed Account Advisors LLC33 0.00% 
    BofA Securities, Inc.00 0.00% 
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
    14,46214,462 0.02% 
    U.S. Trust Company of Delaware121121 0.00% 
    Subtotal269,398264,930 0.40% 
     TOTAL264,93000.40%0.00%



    B) Equivalent financial instrumentsAfter the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  156,8340.24%physical
    BofA Securities, Inc.Right to Recall  29,4000.04%physical
    BofA Securities, Inc.Rights of Use  3,128,4434.75%physical
    Merrill Lynch InternationalRights of Use  3,4210.01%physical
    Bank of America, National AssociationPhysical Call Option19/06/2026 100,0000.15%physical
    Bank of America, National AssociationSwaps15/06/2026 12,5000.02%cash
    Bank of America, National AssociationSwaps15/01/2027 2,6460.00%cash
    Bank of America, National AssociationSwaps15/10/2027 150.00%cash
    Bank of America, National AssociationSwaps31/01/2028 2930.00%cash
    Merrill Lynch InternationalSwaps15/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps15/01/2027 13,8350.02%cash
    Merrill Lynch InternationalSwaps15/10/2027 150.00%cash
    Merrill Lynch InternationalSwaps30/04/2026 10,8700.02%cash
    Merrill Lynch InternationalSwaps02/07/2026 1,2250.00%cash
    Merrill Lynch InternationalSwaps01/11/2027 4,8100.01%cash
    Merrill Lynch InternationalSwaps29/01/2027 5800.00%cash
    Merrill Lynch InternationalSwaps29/12/2026 730.00%cash
    Merrill Lynch InternationalSwaps27/02/2026 3120.00%cash
    Merrill Lynch InternationalSwaps09/09/2027 8210.00%cash
     TOTAL  3,478,5935.28% 



    TOTAL (A&B)# of voting rights% of voting rights
     3,743,5235.68%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    The notification dated February 6, 2026, contains the following information:

    • Date of notification: February 6, 2026
    • Date on which the threshold is crossed: February 3, 2026
    • Threshold of voting rights crossed (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation00 0.00% 
    Bank of America, National Association12,49312,493 0.02% 
    Merrill Lynch International223,291242,319 0.37% 
    Managed Account Advisors LLC33 0.00% 
    BofA Securities, Inc.00 0.00% 
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
    14,46214,462 0.02% 
    U.S. Trust Company of Delaware121121 0.00% 
    Subtotal250,370269,398 0.41% 
     TOTAL269,39800.41%0.00%



    B) Equivalent financial instrumentsAfter the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  156,8340.24%physical
    BofA Securities, Inc.Right to Recall  29,4000.04%physical
    BofA Securities, Inc.Rights of Use  4,145,2946.29%physical
    Merrill Lynch InternationalRights of Use  3,8590.01%physical
    Bank of America, National AssociationPhysical Call Option19/06/2026 100,0000.15%physical
    Bank of America, National AssociationSwaps15/06/2026 12,5000.02%cash
    Bank of America, National AssociationSwaps15/01/2027 2,6460.00%cash
    Bank of America, National AssociationSwaps15/10/2027 150.00%cash
    Bank of America, National AssociationSwaps31/01/2028 2950.00%cash
    Merrill Lynch InternationalSwaps15/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps15/01/2027 13,8350.02%cash
    Merrill Lynch InternationalSwaps15/10/2027 150.00%cash
    Merrill Lynch InternationalSwaps30/04/2026 9,9900.02%cash
    Merrill Lynch InternationalSwaps02/07/2026 1,2980.00%cash
    Merrill Lynch InternationalSwaps01/11/2027 4,6680.01%cash
    Merrill Lynch InternationalSwaps29/01/2027 1,4420.00%cash
    Merrill Lynch InternationalSwaps30/06/2026 1340.00%cash
    Merrill Lynch InternationalSwaps29/12/2026 3130.00%cash
    Merrill Lynch InternationalSwaps27/02/2026 850.00%cash
     TOTAL  4,495,1236.82% 



    TOTAL (A&B)# of voting rights% of voting rights
     4,764,5217.23%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    The notification dated February 5, 2026, contains the following information:

    • Date of notification: February 5, 2026
    • Date on which the threshold is crossed: February 2, 2026
    • Threshold of voting rights crossed (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of voting securities or voting rights and acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation0000.00%0.00%
    Bank of America, National Association12,47612,49300.02%0.00%
    Merrill Lynch International66,430223,29100.34%0.00%
    Managed Account Advisors LLC3300.00%0.00%
    BofA Securities, Inc.10,042000.00%0.00%
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
    14,46214,46200.02%0.00%
    U.S. Trust Company of Delaware12112100.00%0.00%
    Subtotal103,534250,370 0.38% 
     TOTAL250,37000.38%0.00%



    B) Equivalent financial instrumentsAfter the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  156,8350.24%physical
    BofA Securities, Inc.Right to Recall  29,4000.04%physical
    BofA Securities, Inc.Rights of Use  2,919,1644.43%physical
    Merrill Lynch InternationalRights of Use  2,6080.00%physical
    Bank of America, National AssociationPhysical Call Option19/06/2026 100,0000.15%physical
    Merrill Lynch InternationalSwaps19/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps15/06/2026 13,0540.02%cash
    Merrill Lynch InternationalSwaps15/01/2027 150.00%cash
    Merrill Lynch InternationalSwaps30/04/2026 10,0800.02%cash
    Merrill Lynch InternationalSwaps02/07/2026 1,2590.00%cash
    Merrill Lynch InternationalSwaps01/11/2027 4,5200.01%cash
    Merrill Lynch InternationalSwaps29/01/2027 5890.00%cash
    Merrill Lynch InternationalSwaps30/06/2026 390.00%cash
    Merrill Lynch InternationalSwaps29/12/2026 210.00%cash
    Bank of America, National AssociationSwaps15/10/2027 150.00%cash
    Bank of America, National AssociationSwaps15/06/2026 12,5000.02%cash
    Bank of America, National AssociationSwaps15/01/2027 1,8650.00%cash
    Bank of America, National AssociationSwaps31/01/2028 2970.02%cash
     TOTAL  3,264,7614.95% 



    TOTAL (A&B)# of voting rights% of voting rights
     3,515,1315.33%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    For further information, contact Galapagos:

    Investor Relations

    Glenn Schulman

    +1 412 522 6239

    ir@glpg.com

    Media

    Media

    Katie Morris

    +1 952 288 6821

    katiemorris@ententeinc.com

    Visit us at www.glpg.com or follow us on LinkedIn or X.


    1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

    Attachment

    • Galapagos Receives Transparency Notifications from Bank of America


    Primary Logo

    Get the next $GLPG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    10/22/2025$40.00Market Perform → Outperform
    Leerink Partners
    8/5/2025Hold → Sell
    Deutsche Bank
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GLPG
    SEC Filings

    View All

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    2/10/26 5:12:47 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    1/5/26 4:57:09 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    12/18/25 4:32:37 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galapagos Receives Transparency Notifications from Bank of America

    Mechelen, Belgium; February 10, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 5, 6, and 9, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos' voting rights on February 2, 2026, followed by its controlled entity, BofA Securities, Inc., individually crossing the threshold of 5% on February 3, 2026, as a result of an acquisition of Galapagos' voting rights and equivalent

    2/10/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

    Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now co

    1/5/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus

    GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile was consistent with previous studies with GLPG3667 Galapagos will evaluate all strategic alternatives, including resumption of its partnering process, to accelerate further development of GLPG3667 in dermatomyositis and potentially other severe auto-immune indic

    12/18/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galapagos NV upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00

    10/22/25 7:00:32 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Deutsche Bank

    Deutsche Bank downgraded Galapagos NV from Hold to Sell

    8/5/25 3:22:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

    2/14/25 8:06:36 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    View All

    Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

    New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board's composition with the Company's strategic direction and support its focus on transformational business development to build a pipeline of novel medicines in areas of high unmet medical need. Seasoned biopharma executive Dr. Neil Johnston has been appointed to the Board of Directors by way of co-

    10/30/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Appointment of Fred Blakeslee as General Counsel

    Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f

    10/16/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

    Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said

    7/23/25 4:03:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Financials

    Live finance-specific insights

    View All

    Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

    Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now co

    1/5/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

    Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m

    11/5/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

    First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

    4/23/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galapagos NV

    SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

    11/12/24 9:55:16 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Galapagos NV

    SC 13D - GALAPAGOS NV (0001421876) (Subject)

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care